I-MAB (NAS:IMAB)
$ 1.055 -0.04 (-3.64%) Market Cap: 81.84 Mil Enterprise Value: -118.19 Mil PE Ratio: 0 PB Ratio: 0.35 GF Score: 35/100

Half Year 2021 I-Mab Earnings & Corporate Progress Update Conference Call Transcript

Aug 31, 2021 / 12:00PM GMT
Release Date Price: $70.92 (+10.50%)
Jielun Zhu
I-Mab - CFO & Director

Thank you, everyone. Thank you for standing by, and welcome to I-Mab 2021 interim business update and the financial results conference call.

Earlier today, we issued a press release detailing I-Mab's significant pipeline progress and the corporate highlights during the first half of 2021 and upcoming milestones for the rest of 2021 as well as a review of our financial results for the first 6 months in 2021. The press release can be accessed on the investor portion of our website.

Joining me today on the call from I-Mab's senior management team are Dr. Jingwu Zang, our Founder, Chairman and Director; and Dr. Joan Shen, our Chief Executive Officer. Dr. Zang will provide a high-level overview of our recent achievements and the strategy going forward. He will then highlight the progress we have made in our key clinical programs and upcoming milestones and catalysts. Dr. Shen will then comment on the status of other important clinical assets and corporate achievements. I will then provide a brief summary of our financial results and our preparation for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot